drugset / Trial / NCT00384774
A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine
RandomizedParallel-groupDouble-blindTreatment
Summary
This study evaluates the efficacy of a range of intravenous doses of COL-144 in the treatment of migraine headache in order to select a dose range for further studies.
Timeline
- Start
- 2006-11
- Primary completion
- 2007-06
- Completion
- 2007-06
Publications
- Results Reuter U, Pilgrim A, Diener HC, Färkkilä M, Ferrari M for the European COL-144 investigators. COL-144: A Selective 5-HT1F Agonist For the Treatment of Migraine Attacks. European Headache & Migraine Trust International Congress 2008, London, England, Poster #PC.11, September 5, 2008.
- Blumenfeld A, Tepper SJ, Khanna R, Doty E, Vincent M, Miller SI. Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience. Front Neurol. 2023 Oct 27;14:1291102. doi: 10.3389/fneur.2023.1291102. eCollection 2023.
- Ferrari MD, Farkkila M, Reuter U, Pilgrim A, Davis C, Krauss M, Diener HC; European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomised proof-of-concept trial. Cephalalgia. 2010 Oct;30(10):1170-8. doi: 10.1177/0333102410375512. Epub 2010 Jun 15.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lasmiditan | Small molecule | 2.5 mg | Intravenous |
| Subject | Lasmiditan | Small molecule | 5 mg | Intravenous |
| Subject | Lasmiditan | Small molecule | 10 mg | Intravenous |
| Subject | Lasmiditan | Small molecule | 20 mg | Intravenous |
| Subject | Lasmiditan | Small molecule | 30 mg | Intravenous |
| Subject | Lasmiditan | Small molecule | 45 mg | Intravenous |